Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Primary Diffuse Leptomeningeal Melanocytosis, A Diagnoatic Conundrum
Neurol 101:e576-3580, Selvarajan,J.M.P.,et al, 2023
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People with Antiphospholipid Syndrome
Stroke 49:e41-e42, Bala, M.M.,et al, 2018
Infective Endocarditis
Lancet 387:882-893, Cahill, T.J. & Prendergast, B.D., 2016
Tumor Necrosis Factor-Alpha Inhibitors: Risk of Malignancy
UpToDate January, Stone, J.H., 2013
Treatment of Patients with Suspected Ischemic Stroke of Undetermined Onset and Negative Head Computed Tomography Scan
Stroke 44:1494-1495, Adams, H., 2013
A Plain Computed Tomography Scan is Sufficient to Consider Thrombolysis in Patients with Unknown Time of Onset
Stroke 44:1492-1493, Alexandrov, A., 2013
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
PANDAS
www.medlink.com,Feb, Erfe,M.C.B., 2011
Open Biopsy in Patients With Acute Progressive Neurologic Decline and Absence of Mass Lesion
Neurol 75:419-424, Schuette,A.J., et al, 2010
The Case Against Confirmatory Tests for Determining Brain Death in Adults
Neurol 75:77-83, Wijdicks,E.F.M., 2010
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Death by Nondiagnosis: Why Emergent CT Angiography Should Not Be Done for Patients With Subarachnoid Hemorrhage
AJNR 28:1837-1838, Kallmes,D.F.,et al, 2007
The First Seizure and Its Management in Adults and Children
BMJ 332:339-342, Pohlmann-Eden,B.,et al, 2006
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Management of Antiphospholipid Antibody Syndrome, A Systematic Review
JAMA 295:1050-1057, Lim,W.,et al, 2006
Stiff-Person Syndrome
The Neurologist 10:131-137, Murinson,B.B., 2004
Intraarterial Thrombolysis: Ready for Prime Time?
AJNR 22:55-58, Executive Committee of the ASITN, 2001
Intraspinal Steroids: History, Efficacy, Accidentality, and Controversy with Review of United States Food and Drug Administration Reports
JNNP 70:433-443, Nelson,D.A. & Landau,W.M., 2001
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Tectal Gliomas: Natural History of an Indolent Lesion in Pediatric Patients
Pediatr Neurosurg 32:24-29, Bowers,D.C.,et al, 2000
Cryptic Vascular Malformations:Controversies in Terminology, Diagnosis, Pathophysiology, and Treatment
AJNR 18:1839-1846, Dillon,W.P., 1997
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992